Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:MNKD NASDAQ:RGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.70-2.7%$8.41$6.01▼$11.31$1.66B1.132.16 million shs3.12 million shsCLDXCelldex Therapeutics$24.50+0.2%$22.82$14.40▼$47.00$1.62B1.191.58 million shs1.10 million shsMNKDMannKind$5.38-3.4%$4.23$3.38▼$7.63$1.71B1.025.50 million shs6.17 million shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-2.65%-5.98%-8.00%-22.77%-2.78%CLDXCelldex Therapeutics+0.20%+4.70%-3.92%+22.13%-44.52%MNKDMannKind-3.41%-3.41%+44.24%+43.47%-14.19%RGLSRegulus Therapeutics0.00%0.00%0.00%-0.49%+406.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.70-2.7%$8.41$6.01▼$11.31$1.66B1.132.16 million shs3.12 million shsCLDXCelldex Therapeutics$24.50+0.2%$22.82$14.40▼$47.00$1.62B1.191.58 million shs1.10 million shsMNKDMannKind$5.38-3.4%$4.23$3.38▼$7.63$1.71B1.025.50 million shs6.17 million shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-2.65%-5.98%-8.00%-22.77%-2.78%CLDXCelldex Therapeutics+0.20%+4.70%-3.92%+22.13%-44.52%MNKDMannKind-3.41%-3.41%+44.24%+43.47%-14.19%RGLSRegulus Therapeutics0.00%0.00%0.00%-0.49%+406.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.70116.88% UpsideCLDXCelldex Therapeutics 2.78Moderate Buy$46.6790.48% UpsideMNKDMannKind 3.17Buy$11.17107.56% UpsideRGLSRegulus Therapeutics 2.17Hold$8.807.84% UpsideCurrent Analyst Ratings BreakdownLatest RGLS, BCRX, MNKD, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.008/25/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/20/2025CLDXCelldex TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $38.008/20/2025CLDXCelldex TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$56.00 ➝ $48.008/20/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$64.00 ➝ $62.008/20/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $42.008/7/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.008/4/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M3.59N/AN/A($2.30) per share-3.35CLDXCelldex Therapeutics$7.02M231.77N/AN/A$11.26 per share2.18MNKDMannKind$285.50M5.78$0.13 per share40.13($0.29) per share-18.55RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.59-6.41%N/A-1.78%11/3/2025 (Estimated)CLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)MNKDMannKind$27.59M$0.1148.9123.39N/A10.87%-32.60%7.81%11/6/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%N/ALatest RGLS, BCRX, MNKD, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.252.22CLDXCelldex TherapeuticsN/A19.6719.67MNKDMannKindN/A2.502.24RGLSRegulus TherapeuticsN/A16.3116.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/AMNKDMannKind49.55%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%CLDXCelldex Therapeutics4.40%MNKDMannKind3.00%RGLSRegulus Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableMNKDMannKind400306.83 million297.62 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableRGLS, BCRX, MNKD, and CLDX HeadlinesRecent News About These CompaniesNovartis (NVS) Acquires Regulus Therapeutics for $1.7 BillionJune 28, 2025 | finance.yahoo.comNovartis concludes acquisition of Regulus TherapeuticsJune 26, 2025 | medicaldialogues.inMNovartis concludes Regulus Therapeutics acquisitionJune 26, 2025 | pharmaceutical-technology.comPPress Release: Novartis completes acquisition of Regulus TherapeuticsJune 25, 2025 | finanzen.atFNovartis completes acquisition of Regulus TherapeuticsJune 25, 2025 | globenewswire.comNovartis announces expiration of HSR waiting period of Regulus Therapeutics tender offerJune 24, 2025 | pharmabiz.comPRegulus Therapeutics Inc.June 21, 2025 | barrons.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Acquires 12,000 SharesJune 5, 2025 | insidertrades.comInsider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS)June 4, 2025 | gurufocus.comRegulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 PayoutJune 4, 2025 | seekingalpha.comNovartis commences tender offer to acquire Regulus TherapeuticsMay 29, 2025 | pharmabiz.comPNovartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing showsMay 29, 2025 | fiercepharma.comFNovartis arm commences tender offer to buy Regulus TherapeuticsMay 28, 2025 | medicaldialogues.inMLatham and Covington Advise on Novartis’s Acquisition of RegulusMay 16, 2025 | lawstreetmedia.comLRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 9, 2025 | finanznachrichten.deRegulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 8, 2025 | prnewswire.comREGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLSMay 4, 2025 | businesswire.comNovartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion DealMay 4, 2025 | gurufocus.comWells Fargo Downgrades Regulus Therapeutics (RGLS)May 2, 2025 | msn.comNovartis to buy Regulus Therapeutics for as much as $1.7 billionMay 2, 2025 | latimes.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGLS, BCRX, MNKD, and CLDX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$7.70 -0.21 (-2.65%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$7.71 +0.01 (+0.18%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$24.50 +0.05 (+0.20%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$24.16 -0.34 (-1.41%) As of 09/15/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.MannKind NASDAQ:MNKD$5.38 -0.19 (-3.41%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$5.39 +0.01 (+0.17%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
